Clinical Outcomes of Eravacycline in Patients Treated Predominately for Carbapenem-Resistant Acinetobacter baumannii
Forty-six patients were treated with eravacycline (ERV) for Acinetobacter baumannii infections, where 69.5% of isolates were carbapenem resistant (CRAB). Infections were primarily pulmonary (58.3%), and most patients received combination therapy (84.4%). The median (IQR) ERV duration was 6.9 days (5.1 to 11.1). Thirty-day mortality was 23.9% in the cohort and 21.9% in CRAB patients. One patient experienced an ERV-possible adverse event. IMPORTANCE Acinetobacter baumannii, particularly when carbapenem resistant (CRAB), is one of the most challenging pathogens in the health care setting. This is complicated by the fact that there is no consensus guideline regarding management of A. baumannii infections. However, the recent Infectious Diseases Society of America guidelines for treatment of resistant Gram-negative infections provided expert recommendations for CRAB management. The panel suggest using minocycline among tetracycline derivatives rather than eravacycline (ERV) until sufficient clinical data are available. Therefore, we present the largest multicenter real-world cohort in patients treated with ERV for A. baumannii, where the majority of isolates were CRAB (69.5%). Our analysis demonstrate that patients treated with ERV-based regimens achieved a 30-day mortality of 23.9% and had a low incidence of ERV-possible adverse events (2.1%). This study is important as it fills the gap in the literature regarding the use of a novel tetracycline (i.e., ERV) in the treatment of this challenging health care infection.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2022 |
---|---|
Erschienen: |
2022 |
Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
---|---|
Enthalten in: |
Microbiology spectrum - 10(2022), 5 vom: 26. Okt., Seite e0047922 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Alosaimy, Sara [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 28.10.2022 Date Revised 05.02.2024 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1128/spectrum.00479-22 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM347059120 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM347059120 | ||
003 | DE-627 | ||
005 | 20240205231825.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2022 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1128/spectrum.00479-22 |2 doi | |
028 | 5 | 2 | |a pubmed24n1281.xml |
035 | |a (DE-627)NLM347059120 | ||
035 | |a (NLM)36190427 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Alosaimy, Sara |e verfasserin |4 aut | |
245 | 1 | 0 | |a Clinical Outcomes of Eravacycline in Patients Treated Predominately for Carbapenem-Resistant Acinetobacter baumannii |
264 | 1 | |c 2022 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 28.10.2022 | ||
500 | |a Date Revised 05.02.2024 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Forty-six patients were treated with eravacycline (ERV) for Acinetobacter baumannii infections, where 69.5% of isolates were carbapenem resistant (CRAB). Infections were primarily pulmonary (58.3%), and most patients received combination therapy (84.4%). The median (IQR) ERV duration was 6.9 days (5.1 to 11.1). Thirty-day mortality was 23.9% in the cohort and 21.9% in CRAB patients. One patient experienced an ERV-possible adverse event. IMPORTANCE Acinetobacter baumannii, particularly when carbapenem resistant (CRAB), is one of the most challenging pathogens in the health care setting. This is complicated by the fact that there is no consensus guideline regarding management of A. baumannii infections. However, the recent Infectious Diseases Society of America guidelines for treatment of resistant Gram-negative infections provided expert recommendations for CRAB management. The panel suggest using minocycline among tetracycline derivatives rather than eravacycline (ERV) until sufficient clinical data are available. Therefore, we present the largest multicenter real-world cohort in patients treated with ERV for A. baumannii, where the majority of isolates were CRAB (69.5%). Our analysis demonstrate that patients treated with ERV-based regimens achieved a 30-day mortality of 23.9% and had a low incidence of ERV-possible adverse events (2.1%). This study is important as it fills the gap in the literature regarding the use of a novel tetracycline (i.e., ERV) in the treatment of this challenging health care infection | ||
650 | 4 | |a Multicenter Study | |
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 4 | |a Acinetobacter | |
650 | 4 | |a Acinetobacter baumannii | |
650 | 4 | |a CRAB | |
650 | 4 | |a Gram-negative bacteria | |
650 | 4 | |a eravacycline | |
650 | 4 | |a hospital infections | |
650 | 4 | |a tetracyclines | |
650 | 7 | |a Minocycline |2 NLM | |
650 | 7 | |a FYY3R43WGO |2 NLM | |
650 | 7 | |a Carbapenems |2 NLM | |
650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
700 | 1 | |a Morrisette, Taylor |e verfasserin |4 aut | |
700 | 1 | |a Lagnf, Abdalhamid M |e verfasserin |4 aut | |
700 | 1 | |a Rojas, Leonor M |e verfasserin |4 aut | |
700 | 1 | |a King, Madeline A |e verfasserin |4 aut | |
700 | 1 | |a Pullinger, Benjamin M |e verfasserin |4 aut | |
700 | 1 | |a Hobbs, Athena L V |e verfasserin |4 aut | |
700 | 1 | |a Perkins, Nicholson B |c 3rd |e verfasserin |4 aut | |
700 | 1 | |a Veve, Michael P |e verfasserin |4 aut | |
700 | 1 | |a Bouchard, Jeannette |e verfasserin |4 aut | |
700 | 1 | |a Gore, Tristan |e verfasserin |4 aut | |
700 | 1 | |a Jones, Bruce |e verfasserin |4 aut | |
700 | 1 | |a Truong, James |e verfasserin |4 aut | |
700 | 1 | |a Andrade, Justin |e verfasserin |4 aut | |
700 | 1 | |a Huang, Glen |e verfasserin |4 aut | |
700 | 1 | |a Cosimi, Reese |e verfasserin |4 aut | |
700 | 1 | |a Kang-Birken, S Lena |e verfasserin |4 aut | |
700 | 1 | |a Molina, Kyle C |e verfasserin |4 aut | |
700 | 1 | |a Biagi, Mark |e verfasserin |4 aut | |
700 | 1 | |a Pierce, Michael |e verfasserin |4 aut | |
700 | 1 | |a Scipione, Marco R |e verfasserin |4 aut | |
700 | 1 | |a Zhao, Jing J |e verfasserin |4 aut | |
700 | 1 | |a Davis, Susan L |e verfasserin |4 aut | |
700 | 1 | |a Rybak, Michael J |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Microbiology spectrum |d 2013 |g 10(2022), 5 vom: 26. Okt., Seite e0047922 |w (DE-627)NLM241847044 |x 2165-0497 |7 nnns |
773 | 1 | 8 | |g volume:10 |g year:2022 |g number:5 |g day:26 |g month:10 |g pages:e0047922 |
856 | 4 | 0 | |u http://dx.doi.org/10.1128/spectrum.00479-22 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 10 |j 2022 |e 5 |b 26 |c 10 |h e0047922 |